T. Rowe Price Associates
PRAH

T. Rowe Price Associates’s PRA Health Sciences, Inc. PRAH Stock Holding History

T. Rowe Price Associates’s Portfolio PRAH Stock Details PRAH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-54,904
Closed -$9.07M – 3040
2021
Q2 		$9.07M Sell
54,904
-3,478,717
-98% -$581M ﹤0.01% 1430
2021
Q1 		$542M Sell
3,533,621
-3,521,239
-50% -$478M 0.05% 313
2020
Q4 		$885M Sell
7,054,860
-47,048
-0.7% -$5.26M 0.09% 236
2020
Q3 		$720M Sell
7,101,908
-241,255
-3% -$24.6M 0.08% 244
2020
Q2 		$714M Sell
7,343,163
-38,474
-0.5% -$3.58M 0.09% 234
2020
Q1 		$613M Buy
7,381,637
+485,952
+7% +$47.4M 0.1% 221
2019
Q4 		$766M Buy
6,895,685
+525,629
+8% +$54.1M 0.1% 216
2019
Q3 		$632M Buy
6,370,056
+1,670,484
+36% +$166M 0.09% 239
2019
Q2 		$466M Buy
4,699,572
+3,967,806
+542% +$379M 0.07% 288
2019
Q1 		$80.7M Buy
731,766
+8,156
+1% +$852K 0.01% 699
2018
Q4 		$66.5M Buy
723,610
+29,236
+4% +$2.96M 0.01% 715
2018
Q3 		$76.5M Buy
694,374
+76,136
+12% +$7.93M 0.01% 759
2018
Q2 		$57.7M Buy
618,238
+125,436
+25% +$10.8M 0.01% 841
2018
Q1 		$40.9M Buy
492,802
+53,685
+12% +$4.77M 0.01% 946
2017
Q4 		$40M Buy
439,117
+44,874
+11% +$3.73M 0.01% 949
2017
Q3 		$30M Buy
394,243
+40,911
+12% +$3.09M 0.01% 1044
2017
Q2 		$26.5M Buy
353,332
+36,754
+12% +$2.55M ﹤0.01% 1068
2017
Q1 		$20.6M Buy
316,578
+70,650
+29% +$4.16M ﹤0.01% 1151
2016
Q4 		$13.6M Buy
245,928
+12,160
+5% +$667K ﹤0.01% 1247
2016
Q3 		$13.2M Buy
233,768
+59,918
+34% +$2.94M ﹤0.01% 1255
2016
Q2 		$7.26M Buy
+173,850
New +$8.01M ﹤0.01% 1344

Other funds holding PRAH

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

T. Rowe Price Associates's PRAH Position: Q3 2021 in Review

T. Rowe Price Associates sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 54,904 shares — an estimated $9.07M sold.

T. Rowe Price Associates first reported a position in PRAH in Q2 2016 and held it in 21 quarters. The position peaked at $885M in Q4 2020. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.

  • T. Rowe Price Associates reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 54,904 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $9.07M.
  • T. Rowe Price Associates first reported a position in PRA Health Sciences, Inc. in Q2 2016 and held it in 21 quarters.
  • T. Rowe Price Associates's PRA Health Sciences, Inc. position peaked at $885M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.

Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.